Expression of BSAP in cHD
| Case No. . | Diagnosis . | BSAP IH . | BSAP ISH . | CD20 (%) . |
|---|---|---|---|---|
| 1 | NS, EBV+ | ++++ | ++++ | 30 |
| 2 | NS | ++++ | ++++ | 15 |
| 3 | NS | ++++ | ++++ | — |
| 4 | NS | ++++ | ++++ | 50 |
| 5 | NS | ++++ | ++++ | — |
| 6 | NS | ++++ | ++++ | — |
| 7 | MC, EBV+ | ++++ | +++ | — |
| 8 | MC, EBV+ | ++++ | +++ | — |
| 9 | NS | ++++ | ++ | — |
| 10 | NS | ++++ | ++ | — |
| 11 | MC, EBV+ | ++++ | ++ | <10 |
| 12 | MC, EBV+ | ++++ | ++ | — |
| 13 | MC, EBV+ | ++++ | + | — |
| 14 | MC, EBV+ | ++++ | (+) | — |
| 15 | NS | ++++ | (+) | — |
| 16 | MC, EBV+ | ++++ | (+) | — |
| 17 | MC, EBV+ | ++++ | ND | 50 |
| 18 | MC, EBV+ | ++++ | ND | — |
| 19 | MC, EBV+ | ++++ | ND | ND |
| 20 | MC, EBV+ | ++++ | ND | ND |
| 21 | MC, EBV+ | ++++ | ND | — |
| 22 | NS, EBV+ | +++ | ND | ND |
| 23 | NS | ++ | ++ | — |
| 24 | MC, EBV+ | ++ | (+) | — |
| 25 | NS | ++ | ND | ND |
| 26 | MC, EBV+ | ++ | — | ND |
| 27 | NS | + | — | — |
| 28 | NS | pos.* | +++ | — |
| 29 | MC, EBV+ | ND | +++ | — |
| 30 | MC, EBV+ | ND | ++++ | — |
| 31 | NS | — | ++ | <10 |
| 32 | NS, EBV+ | — | ND | <10 |
| NS | — | — | <10 | |
| 33 | MC | — | ND | ND |
| Case No. . | Diagnosis . | BSAP IH . | BSAP ISH . | CD20 (%) . |
|---|---|---|---|---|
| 1 | NS, EBV+ | ++++ | ++++ | 30 |
| 2 | NS | ++++ | ++++ | 15 |
| 3 | NS | ++++ | ++++ | — |
| 4 | NS | ++++ | ++++ | 50 |
| 5 | NS | ++++ | ++++ | — |
| 6 | NS | ++++ | ++++ | — |
| 7 | MC, EBV+ | ++++ | +++ | — |
| 8 | MC, EBV+ | ++++ | +++ | — |
| 9 | NS | ++++ | ++ | — |
| 10 | NS | ++++ | ++ | — |
| 11 | MC, EBV+ | ++++ | ++ | <10 |
| 12 | MC, EBV+ | ++++ | ++ | — |
| 13 | MC, EBV+ | ++++ | + | — |
| 14 | MC, EBV+ | ++++ | (+) | — |
| 15 | NS | ++++ | (+) | — |
| 16 | MC, EBV+ | ++++ | (+) | — |
| 17 | MC, EBV+ | ++++ | ND | 50 |
| 18 | MC, EBV+ | ++++ | ND | — |
| 19 | MC, EBV+ | ++++ | ND | ND |
| 20 | MC, EBV+ | ++++ | ND | ND |
| 21 | MC, EBV+ | ++++ | ND | — |
| 22 | NS, EBV+ | +++ | ND | ND |
| 23 | NS | ++ | ++ | — |
| 24 | MC, EBV+ | ++ | (+) | — |
| 25 | NS | ++ | ND | ND |
| 26 | MC, EBV+ | ++ | — | ND |
| 27 | NS | + | — | — |
| 28 | NS | pos.* | +++ | — |
| 29 | MC, EBV+ | ND | +++ | — |
| 30 | MC, EBV+ | ND | ++++ | — |
| 31 | NS | — | ++ | <10 |
| 32 | NS, EBV+ | — | ND | <10 |
| NS | — | — | <10 | |
| 33 | MC | — | ND | ND |
Abbreviations: ND, not determined; ++++, +++, ++, +, (+) signify labeling of more than 75%, 50%, 25%, 10% and <10% of neoplastic cells; MC, HD mixed cellularity type; NS, HD nodular sclerosis type; EBV+, expression of EBER molecules or the EBV-encoded latent membrane protein in the neoplastic cells.
This case contained labeled HRS cells; however, the percentage could not be determined because of staining inhomogeneity.
In case 32, 2 biopsy samples from the same patient were examined: in this case, the HRS cells lost the EBV during the disease course, as published recently.36